Related Experiment Video
Updated: Jun 7, 2025
Quantifying the Brain Metastatic Tumor Micro-Environment using an Organ-On-A Chip 3D Model, Machine Learning, and Confocal Tomography
Published on: August 16, 2020
Integrating multi-omics data reveals neuroblastoma subtypes in the tumor microenvironment
Jinhua Fan1, Shuxin Tang1, Xiangru Kong2
1Pediatric Research Institute, Chongqing Key Laboratory of Child Neurodevelopment and Cognitive Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, National Clinical Research Center for Child Health and Disorders, Children's Hospital of Chongqing Medical University, Chongqing 400014, China.
Researchers identified three neuroblastoma (NB) subtypes using network fusion: mesenchymal-like (MES), MYCN-like (MYCN), and neurogenic-like (Neurogenic). This classification aids in developing targeted therapies for this severe pediatric cancer.
Area of Science:
- Pediatric Oncology
- Computational Biology
- Systems Biology
Background:
- Neuroblastoma (NB) is a severe pediatric cancer with variable outcomes, indicating distinct subtypes.
- Accurate NB classification is crucial for developing effective, targeted treatments.
Purpose of the Study:
- To classify neuroblastoma into biologically distinct subtypes using an integrative multi-omics approach.
- To characterize the tumor microenvironment and predict drug sensitivity for each identified subtype.
Main Methods:
- Employed the similarity network fusion (SNF) algorithm to integrate multi-omics data.
- Utilized single-cell RNA sequencing (scRNA-seq) to analyze tumor microenvironments.
- Performed drug sensitivity prediction analysis.
Main Results:
- Identified three NB subtypes: mesenchymal-like (MES), MYCN-like (MYCN), and neurogenic-like (Neurogenic).
- MES subtype shows immune pathway activation; MYCN subtype has poor prognosis and cell growth pathways; Neurogenic subtype has good prognosis and sympathetic nervous system development pathways.
- Discovered divergent adrenergic cell differentiation and identified unique immune cell populations (naïve T cells) and mesenchymal subtypes within specific NB subtypes.
- Predicted MEK inhibitors for MES subtype and Bcl-2 inhibitors for MYCN subtype.
Conclusions:
- The integrative multi-omics approach successfully stratified NB into distinct subtypes.
- This precise stratification provides a foundation for developing subtype-specific therapeutic strategies.
- The findings offer potential for improved patient management and survival outcomes in neuroblastoma.
